Reviva Pharmaceuticals (NASDAQ:RVPH) Rating Increased to Hold at Wall Street Zen

Reviva Pharmaceuticals (NASDAQ:RVPH) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

Other analysts have also issued reports about the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research report on Wednesday, October 8th. Benchmark reduced their price objective on Reviva Pharmaceuticals from $14.00 to $7.00 and set a “speculative buy” rating for the company in a research note on Monday, September 15th. HC Wainwright restated a “buy” rating and set a $4.00 price objective on shares of Reviva Pharmaceuticals in a report on Tuesday. D. Boral Capital reiterated a “buy” rating and issued a $2.00 target price on shares of Reviva Pharmaceuticals in a report on Tuesday. Finally, Chardan Capital raised shares of Reviva Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, November 19th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Reviva Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $3.86.

Reviva Pharmaceuticals Stock Up 10.4%

Shares of NASDAQ RVPH opened at $0.31 on Friday. The firm has a market cap of $35.31 million, a PE ratio of -0.67 and a beta of -0.02. The company’s fifty day simple moving average is $0.55 and its 200 day simple moving average is $0.51. Reviva Pharmaceuticals has a 12-month low of $0.25 and a 12-month high of $2.17.

Reviva Pharmaceuticals (NASDAQ:RVPH) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.05. On average, equities analysts predict that Reviva Pharmaceuticals will post -0.97 earnings per share for the current year.

Institutional Investors Weigh In On Reviva Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Millennium Management LLC lifted its stake in Reviva Pharmaceuticals by 15.0% during the 3rd quarter. Millennium Management LLC now owns 1,711,221 shares of the company’s stock valued at $631,000 after acquiring an additional 223,178 shares in the last quarter. Lido Advisors LLC purchased a new stake in shares of Reviva Pharmaceuticals in the third quarter valued at about $37,000. 683 Capital Management LLC bought a new position in shares of Reviva Pharmaceuticals during the second quarter valued at about $381,000. Armistice Capital LLC purchased a new position in Reviva Pharmaceuticals during the second quarter worth about $1,026,000. Finally, XTX Topco Ltd purchased a new position in Reviva Pharmaceuticals during the second quarter worth about $31,000. 63.18% of the stock is owned by hedge funds and other institutional investors.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.